Diagnostic Rationale And Biofluid Selection
- Central Nervous System (CNS) tumors are the leading cause of pediatric cancer mortality.
- Traditional surgical biopsies for deep-seated tumors, such as Diffuse Midline Gliomas (DMG) or Diffuse Intrinsic Pontine Gliomas (DIPG), carry massive risks of permanent neurological morbidity or hemorrhage.
- Spatial tissue biopsies fail to capture massive tumor heterogeneity and evolutionary changes under therapeutic pressure.
- Cerebrospinal Fluid (CSF) Supremacy: The intact Blood-Brain Barrier (BBB) severely restricts the shedding of circulating tumor DNA (ctDNA) into systemic plasma, yielding diagnostic sensitivities below 5%.
- CSF bathes the tumor directly, providing a highly enriched ctDNA source with diagnostic sensitivities exceeding 85% to 90% via safe lumbar puncture or Ommaya reservoir access.
Core Tumor-Derived Biomarkers
- Circulating Tumor DNA (ctDNA): Fragmented DNA analyzed for point mutations, copy number variations (CNVs), and epigenetic methylation patterns.
- Extracellular Vesicles (EVs): Microvesicles containing functional proteins and microRNAs that mirror the physiological state of the parental tumor.
- Circulating Tumor Cells (CTCs): Intact cells used primarily for evaluating leptomeningeal dissemination patterns in high-grade malignancies.
Advanced Molecular Technologies (2025–2026)
| Technology | Clinical Utility And Performance |
|---|---|
| Digital Droplet PCR (ddPCR) | Absolute quantification of target DNA; detects the pathognomonic H3K27M mutation in DMG with near 90% sensitivity at diagnosis. |
| Nanopore Sequencing & lpWGS | Provides rapid turnaround (48–72 hours) for detecting major CNVs and gene amplifications, such as MYC in medulloblastoma or PDGFRA in secondary gliomas. |
| M-PACT (AI Integration) | Methylation-based Predictive Algorithm for CNS Tumors utilizes an Artificial Intelligence (AI) deep neural network trained on over 5,000 profiles. Achieves 92% classification accuracy for embryonal CNS tumors directly from sub-nanogram CSF ctDNA, eliminating tissue requirements. |
Key Clinical Applications
| Clinical Domain | Application Details |
|---|---|
| Inoperable Tumors | Provides molecular confirmation for surgically inaccessible lesions (e.g., detecting BRAF-KIAA1549 fusions in diffuse leptomeningeal glioneuronal tumors) to initiate targeted MEK inhibitors. |
| Pseudoprogression Differentiation | Falling or undetectable ctDNA levels differentiate treatment-induced radiation necrosis (pseudoprogression) from true tumor progression, preventing unnecessary rescue therapies. |
| Minimal Residual Disease (MRD) | Serial CSF sampling tracks variant allele frequencies, identifying molecular relapse months before visible structural recurrence or leptomeningeal seeding appears on surveillance MRI. |
Global Guidelines And Indian Implementation
- WHO Alignment: Liquid biopsy fulfills the 2021 WHO CNS5 classification mandates requiring molecular diagnostics when physical biopsy is anatomically contraindicated.
- Indian Context: Comprehensive genomic sequencing remains astronomically cost-prohibitive in Low- and Middle-Income Countries (LMICs).
- Pragmatic Strategy: Tertiary Indian centers (e.g., Tata Memorial Hospital, AIIMS) successfully utilize highly specific, affordable ddPCR panels targeting high-yield regional mutations (e.g., H3K27M or MYD88).
- Resource Optimization: Replacing high-risk neurosurgical biopsies with simple lumbar punctures serves as a massive cost-saving measure in developing healthcare systems, allowing resource reallocation toward definitive chemotherapy or palliative care.